{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Intravenous&page=97",
    "query": {
      "intervention": "Placebo Intravenous",
      "page": 97
    },
    "page_size": 10
  },
  "pagination": {
    "page": 97,
    "page_size": 10,
    "total_count": 2352,
    "total_pages": 236,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Intravenous&page=98&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Intravenous&page=96&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-01T04:23:03.177Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06335173",
      "title": "A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alzheimer Disease"
      ],
      "interventions": [
        {
          "name": "sabirnetug",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Acumen Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "50 Years to 90 Years"
      },
      "enrollment_count": 542,
      "start_date": "2024-02-29",
      "completion_date": "2026-10",
      "has_results": false,
      "last_update_posted_date": "2025-10-27",
      "last_synced_at": "2026-11-01T04:23:03.177Z",
      "location_count": 44,
      "location_summary": "Carlsbad, California • Fullerton, California • Irvine, California + 40 more",
      "locations": [
        {
          "city": "Carlsbad",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Santa Ana",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06335173"
    },
    {
      "nct_id": "NCT03636269",
      "title": "CR845-CLIN3103: A Global Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Uremic Pruritus"
      ],
      "interventions": [
        {
          "name": "CR845 0.5 mcg/kg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cara Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 473,
      "start_date": "2018-07-17",
      "completion_date": "2020-03-30",
      "has_results": true,
      "last_update_posted_date": "2022-04-26",
      "last_synced_at": "2026-11-01T04:23:03.177Z",
      "location_count": 29,
      "location_summary": "Chula Vista, California • Fountain Valley, California • Northridge, California + 25 more",
      "locations": [
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Northridge",
          "state": "California"
        },
        {
          "city": "Riverside",
          "state": "California"
        },
        {
          "city": "San Dimas",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03636269"
    },
    {
      "nct_id": "NCT05872958",
      "title": "Dose Exploration Intramuscular/Intravenous Prophylaxis Pharmacokinetic Exposure Response Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "AZD3152",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 98,
      "start_date": "2023-05-19",
      "completion_date": "2024-08-20",
      "has_results": false,
      "last_update_posted_date": "2025-06-06",
      "last_synced_at": "2026-11-01T04:23:03.177Z",
      "location_count": 4,
      "location_summary": "Anniston, Alabama • Cullman, Alabama • Scottsdale, Arizona + 1 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Cullman",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05872958"
    },
    {
      "nct_id": "NCT04295538",
      "title": "Safety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To Assess Change In Upper Extremity Motor Score (UEMS) In Adult Participants With Acute Traumatic Cervical Spinal Cord Injury (SCI)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Spinal Cord Injury (SCI)"
      ],
      "interventions": [
        {
          "name": "Elezanumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 60,
      "start_date": "2020-09-06",
      "completion_date": "2026-01-26",
      "has_results": false,
      "last_update_posted_date": "2026-02-11",
      "last_synced_at": "2026-11-01T04:23:03.177Z",
      "location_count": 22,
      "location_summary": "Sacramento, California • Atlanta, Georgia • Chicago, Illinois + 15 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04295538"
    },
    {
      "nct_id": "NCT04334135",
      "title": "The Influence of Mitochondrial-Derived Reactive Oxygen Species on Racial Disparities in Neurovascular Function",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Racial Disparities",
        "Blood Pressure",
        "Cardiovascular Risk Factor",
        "Renal Function"
      ],
      "interventions": [
        {
          "name": "MitoQ",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Auburn University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "19 Years to 75 Years"
      },
      "enrollment_count": 60,
      "start_date": "2020-10-02",
      "completion_date": "2025-08-31",
      "has_results": false,
      "last_update_posted_date": "2024-05-29",
      "last_synced_at": "2026-11-01T04:23:03.177Z",
      "location_count": 1,
      "location_summary": "Auburn, Alabama",
      "locations": [
        {
          "city": "Auburn",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04334135"
    },
    {
      "nct_id": "NCT00571324",
      "title": "Effect of Exendin-(9-39) on Glycemic Control in Subjects With Congenital Hyperinsulinism",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Congenital Hyperinsulinism"
      ],
      "interventions": [
        {
          "name": "Exendin-(9-39)",
          "type": "DRUG"
        },
        {
          "name": "Vehicle",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Diva De Leon",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "7 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "7 Years to 60 Years"
      },
      "enrollment_count": 9,
      "start_date": "2007-08",
      "completion_date": "2014-12",
      "has_results": true,
      "last_update_posted_date": "2017-12-11",
      "last_synced_at": "2026-11-01T04:23:03.177Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00571324"
    },
    {
      "nct_id": "NCT03263442",
      "title": "High Dose Intravenous Thiamine for the Prevention of Delirium in Allogeneic Hematopoietic Stem Cell Transplantation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hematopoietic Stem Cell Transplantation",
        "Delirium",
        "Thiamine Deficiency"
      ],
      "interventions": [
        {
          "name": "Thiamine",
          "type": "DRUG"
        },
        {
          "name": "Normal saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "UNC Lineberger Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 66,
      "start_date": "2017-10-16",
      "completion_date": "2020-08-10",
      "has_results": true,
      "last_update_posted_date": "2021-10-19",
      "last_synced_at": "2026-11-01T04:23:03.177Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03263442"
    },
    {
      "nct_id": "NCT05267886",
      "title": "CAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Shock, Cardiogenic"
      ],
      "interventions": [
        {
          "name": "Dobutamine",
          "type": "DRUG"
        },
        {
          "name": "Milrinone",
          "type": "DRUG"
        },
        {
          "name": "Normal Saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ottawa Heart Institute Research Corporation",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 346,
      "start_date": "2022-03-05",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-05-01",
      "last_synced_at": "2026-11-01T04:23:03.177Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05267886"
    },
    {
      "nct_id": "NCT03988842",
      "title": "Standard-dose Apixaban AFtEr Very Low-dose ThromboLYSis for Acute Intermediate-high Risk Acute Pulmonary Embolism",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Pulmonary Embolism With Acute Cor Pulmonale",
        "Pulmonary Embolism",
        "Pulmonary Embolism With Pulmonary Infarction",
        "Pulmonary Embolism Subacute Massive",
        "Right Ventricular Dysfunction",
        "Right Ventricular Failure"
      ],
      "interventions": [
        {
          "name": "Alteplase",
          "type": "DRUG"
        },
        {
          "name": "Unfractionated heparin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Apixaban",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Victor Tapson, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 4,
      "start_date": "2019-07-25",
      "completion_date": "2020-04-05",
      "has_results": true,
      "last_update_posted_date": "2021-06-11",
      "last_synced_at": "2026-11-01T04:23:03.177Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03988842"
    },
    {
      "nct_id": "NCT03118570",
      "title": "A Study in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With BPS804",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Osteogenesis Imperfecta, Type I",
        "Osteogenesis Imperfecta Type III",
        "Osteogenesis Imperfecta Type IV"
      ],
      "interventions": [
        {
          "name": "setrusumab",
          "type": "DRUG"
        },
        {
          "name": "Calcium",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Vitamin D",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "zoledronic acid (optional)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Ultragenyx Pharmaceutical Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 112,
      "start_date": "2017-09-11",
      "completion_date": "2020-11-12",
      "has_results": true,
      "last_update_posted_date": "2023-07-05",
      "last_synced_at": "2026-11-01T04:23:03.177Z",
      "location_count": 12,
      "location_summary": "Birmingham, Alabama • Jacksonville, Florida • Baltimore, Maryland + 9 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Saint Paul",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03118570"
    }
  ]
}